Continuing Care Following Drug Abuse Treatment: Linkage With Primary Care

This study is enrolling participants by invitation only.

Sponsor:

Collaborator:

Kaiser Foundation Research Institute

Information provided by (Responsible Party):

Constance Weisner, University of California, San Francisco

ClinicalTrials.gov Identifier:

NCT01621711

First received: June 11, 2012

Last updated: June 13, 2012

Last verified: June 2012

History of Changes

Purpose

This component of a larger Center of Research Excellence Grant improves treatment for drug abuse by developing effective linkages between specialty drug treatment and primary health care.

Condition	Intervention
Substance Abuse Substance Dependence Substance, Addiction Alcohol Abuse	Behavioral: patient activation intervention

Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Health Services Research
Official Title:	Continuing Care Following Drug Abuse Treatment: Linkage With Primary Care

Further study details as provided by University of California, San Francisco:

Primary Outcome Measures:

Number of primary care visits, prevention visits and patient prevention Behaviors [ Time Frame: 24 months post baseline ] [ Designated as safety issue: No ]
Number of drug, alcohol and cigarette abstinence days [ Time Frame: 24 months post baseline ] [ Designated as safety issue: No ]
Number of patients with significant changes in health and psychosocial measurements [ Time Frame: 24 months post baseline ] [ Designated as safety issue: No ]
Amount of emergency room and inpatient costs versus primary care costs [ Time Frame: 24 months post baseline ] [ Designated as safety issue: No ]

Estimated Enrollment:	700
Study Start Date:	March 2011
Estimated Study Completion Date:	June 2015
Estimated Primary Completion Date:	June 2015 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
No Intervention: Usual Primary Care
Usual Primary Care plus Continuing Care Primary Care plus three continuing care elements: 1) a 1-1/2 hour group session on activation regarding overall health behaviors and a 1-1/2 hour group session on selecting a PC physician and communicating with him/her, and 2) a linkage phone call with the patient, clinician, and PC physician.	Behavioral: patient activation intervention Delivered by a clinical psychologist: 1) a 1-1/2 hour group session on activation regarding overall health behaviors and 2) a 1-1/2 hour group session on selecting a PC physician and communicating with him/her, and 3) a linkage phone call with the patient, clinician, and PC physician.

Detailed Description:

This is a longitudinal two-arm quasi-experimental 2-month alternating off/on design over a 20 month period in which, after a random start, the Continuing Care condition alternately is added to Usual Care in the clinic and then removed. We compare Usual Care to Usual Care plus Continuing Care. Follow-up interviews will be conducted at 6, 12 and 24 months. The Continuing Care intervention includes Usual Care plus sessions on activation regarding overall health behaviors and on selecting a PC physician and communicating with him/her, and 2) a linkage phone call with the patient, clinician, and Primary Care physician. The linkage conference call is set up as a phone consult appointment in the physician's and clinician's schedules in the EMR. The design also includes a 1-hour informational session for PC physicians during a lunch staff meeting to inform them of the linkage, information on where to find guidelines in the EMR, and also an EMR alert reminder to the PC Physician before the patient's visit. The intervention aims to place drug abuse problems in the context of overall health and health care and to activate patients to increase involvement in their own health care.

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

United States, California
Kaiser Permanente, Chemical Dependency Recovery Program
San Francisco, California, United States, 94115

Responsible Party:	Constance Weisner, Professor, Department of Psychiatry and Langley Porter Psychiatric Institute, University of California, San Francisco and Associate Director for Health Services Research, University of California, San Francisco
ClinicalTrials.gov Identifier:	NCT01621711 History of Changes
Other Study ID Numbers:	10-01606
Study First Received:	June 11, 2012
Last Updated:	June 13, 2012
Health Authority:	United States: Institutional Review Board